Literature DB >> 31701945

Recommendations on the use of MF59-Adjuvanted Trivalent Influenza Vaccine (Fluad®): Supplemental Statement of Seasonal Influenza Vaccine for 2011-2012 An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI)†.

.   

Abstract

Entities:  

Year:  2011        PMID： 31701945      PMCID： PMC6802457          DOI： 10.14745/ccdr.v37i00a06

Source DB:  PubMed          Journal:  Can Commun Dis Rep        ISSN： 1188-4169


× No keyword cloud information.
  34 in total

1.  Comparison of three different influenza vaccines in institutionalised elderly.

Authors:  V Baldo; T Menegon; C Bonello; A Floreani; R Trivello
Journal:  Vaccine       Date:  2001-05-14       Impact factor: 3.641

2.  Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a non-adjuvanted influenza vaccine in non-elderly adults.

Authors:  Sharon Frey; Gregory Poland; Sandra Percell; Audino Podda
Journal:  Vaccine       Date:  2003-10-01       Impact factor: 3.641

Review 3.  MF59™ as a vaccine adjuvant: a review of safety and immunogenicity.

Authors:  Hana El Sahly
Journal:  Expert Rev Vaccines       Date:  2010-10       Impact factor: 5.217

4.  MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications.

Authors:  V Baldo; T Baldovin; A Floreani; A M Carraro; R Trivello
Journal:  Vaccine       Date:  2007-03-06       Impact factor: 3.641

5.  Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly.

Authors:  Iris de Bruijn; Ingo Meyer; Lisya Gerez; Jos Nauta; Katinka Giezeman; Bram Palache
Journal:  Vaccine       Date:  2007-11-12       Impact factor: 3.641

6.  An influenza A/H3 outbreak during the 2004/2005 winter in elderly vaccinated people living in a nursing home.

Authors:  A M Iorio; M Neri; E Lepri; B Camilloni; M Basileo; N Sigismondi; C Fabiani; L Calzoletti; S Puzelli; I Donatelli
Journal:  Vaccine       Date:  2006-06-05       Impact factor: 3.641

7.  Evidence of increased clinical protection of an MF59-adjuvant influenza vaccine compared to a non-adjuvant vaccine among elderly residents of long-term care facilities in Italy.

Authors:  A Iob; G Brianti; E Zamparo; T Gallo
Journal:  Epidemiol Infect       Date:  2005-08       Impact factor: 2.451

8.  Immunogenicity of three different influenza vaccines against homologous and heterologous strains in nursing home elderly residents.

Authors:  Vincenzo Baldo; Tatjana Baldovin; Michele Pellegrini; Gabriele Angiolelli; Silvia Majori; Annarosa Floreani; Marta Cecilia Busana; Chiara Bertoncello; Renzo Trivello
Journal:  Clin Dev Immunol       Date:  2010-03-29

9.  An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine.

Authors:  Giuseppe Del Giudice; Anne Katrin Hilbert; Roberto Bugarini; Ada Minutello; Olga Popova; Daniela Toneatto; Ines Schoendorf; Astrid Borkowski; Rino Rappuoli; Audino Podda
Journal:  Vaccine       Date:  2006-01-19       Impact factor: 3.641

10.  Safety and immunogenicity of an MF59-adjuvanted subunit influenza vaccine in elderly Chinese subjects.

Authors:  Rongcheng Li; Hanhua Fang; Yanping Li; Youping Liu; Michele Pellegrini; Audino Podda
Journal:  Immun Ageing       Date:  2008-02-20       Impact factor: 6.400
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.